DNLI News and Press, Denali Therapeutics Inc. From 10/12/20

Sarepta has a diversified portfolio of 43 programs including 27 gene therapy and 14 RNA programs. The pipeline is spread between discovery (21) and commercial (2) medicines. The current valuation for Sarepta is comparable to the group of 6 gene therapy companies acquired between 2017 ...

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today announced the signin...

— Webinar scheduled for Thursday, October 15 th at 1:00 p.m. Eastern Time — SOUTH SAN FRANCISCO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineer...

Biogen purchases ~13.3M shares of Denali Therapeutics (DNLI) on September 22.This represents 11.16% of total shares outstanding.The stake does not allow for activism.Press Release For further details see: Biogen reports 11.16% passive stake in Denali Therapeutics

Quick Take Inhibikase Therapeutics ( IKT ) intends to raise $25 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is advancing a pipeline of treatment candidates for neurodegenerative and cancer diseases. IKT is still at a ...

The following slide deck was published by Denali Therapeutics Inc. in conjunction with this Read more ...

BioMarin ( BMRN ) received a complete response letter or CRL for their hemophilia A gene therapy Valrox last week. As a result, the earliest commercial launch is now in 2023. Audentes ( ALPMF ) provided an update on their please 3 neuromuscular ASPIRO clinical trial indicating a third pati...

Denali Therapeutics ( DNLI ) has been on my radar for a while due to my personal interest in companies researching longevity-related areas like neurodegeneration. I hadn’t yet taken a close look, though, until I saw the Biogen ( BIIB ) partnership announcement recently. In this article,...

Genomic medicine, the next major biotech era, is primarily pre-commercial though a few medicines have been approved. The list of FDA-approved cellular and gene therapy products did increase in July when the second Kite Pharma ( GILD ) cell therapy - Tecartus - was approved for relapsed/refract...

COVID-19 Pandemic BioKangtai (SHZ: 300601), a Guangdong vaccine company, in-licensed rights to develop, manufacture and market AstraZeneca's (AZN) COVID-19 vaccine in China. The candidate is an adenovirus vector-based COVID-19 vaccine that was created by Oxford University and partnered b...